Dr Pyrzyńska Team

Beata Pyrzyńska, PhD

The team carries research in the following areas:

•  Development of therapeutic alternatives in combination with monoclonal antibodies for cancer therapy
• Characterization of tumoral, metabolic and immune cross talks, controlling malignant growth and affecting cancer therapies
• Molecular mechanisms regulating endocytic and exocytic pathways in cells

In our projects we use methods of molecular biology, genetic modification of cells, variety of functional tests, flow cytometry, immunophenotyping, bioinformatics and mouse models of tumors

Principal Investigator

Dr Beata Pyrzyńska:   Adjunkt at Immunoloy Department of Medical University in Warsaw

Visiting Researcher:

• Oct.-Nov. 2018: The Francis Crick Institute, London, United Kingdom, collaboration with Prof. Dinis Calado
• June-July 2018: International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy, collaboration with Prof. Dimitar Efremov
• Feb.-March and Oct.-Nov. 2017: International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy, collaboration with Prof. Dimitar Efremov
• August-Sept. 2016: The Francis Crick Institute, London, United Kingdom, collaboration with Prof. Dinis Calado
• June-July 2015: Inserm, U1068, Centre Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, CNRS, UMR7258, Aix-Marseille University, Marseille, France, collaboration with Dr. Cyril Fauriat
• 2002 -2006:     PostDoctoral Fellow, Lab. of Prof. E.G. Van Meir, Dept. of Neuro-Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, US;
• Feb.-July 1999 and Oct. 2000: EMBO Fellowship, National Center of Biotechnology, Dept. of Immunology and Oncology, Madrid, Spain; Collaboration with Dr. M. Serrano and Prof. C. Martinez-A;
• May-Aug. 1995: Research Fellowship, Institute of General Pathology, Perugia, Italy

Memberships:

• American Association for Cancer Research (AACR)

Editorships & Reviewing boards:

• Cellular and Molecular Neurobiology (CEMN)

Scientific advisor & consultant: Abdessamad Zerrouqi, PhD

Postdoctoral Fellows: dr Anna Toruń

Komórki NK z indukowalną ekspresją CAR jako nowa immunoterapia zwiększająca skuteczność przeciwciał monoklonalnych.

Narodowe Centrum Nauki, Progam OPUS, Lata realizacji: 2017-2020, Kierownik: Beata Pyrzyńska

2019

 Sasi B.K., Martines C., Xerxa E., Porro F., Kalkan H., Fazio R., Turkalj S., Bojnik E., Pyrzynska B., Stachura J., Zerrouqi A., Bobrowicz M., Winiarska M., Priebe V., Bertoni F., Mansouri L., Rosenquist R., Efremov D.G. (2019). Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma. Leukemia doi: 10.1038/s41375-019-0442-8. [Epub ahead of print] https://www.nature.com/articles/s41375-019-0442-8

 2018

 Pyrzynska B., Dwojak M., Zerrouqi A., Morlino G., Zapala P., Miazek N., Zagozdzon A., Bojarczuk K., Bobrowicz M., Siernicka M., Machnicki M.M., Gobessi S., Barankiewicz J., Lech-Maranda E., Efremov D.G., Juszczynski P., Calado D., Golab J., Winiarska M. (2018). FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy. Oncoimmunology 7(5):e1423183. doi:10.1080/2162402X.2017.1423183. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927521/

 2017

 Bobrowicz M., Dwojak M., Pyrzynska B., Stachura J., Muchowicz A., Berthel E., Dalla-Venezia N., Kozikowski M., Siernicka M., Miazek N., Zapala P., Domagala A., Bojarczuk K., Malenda A., Barankiewicz J., Graczyk-Jarzynka A., Zagozdzon A., Gabrysiak M., Diaz J.J., Karp M., Lech-Maranda E., Firczuk M., Giannopoulos K., Efremov D.G., Laurenti L., Baatout D., Frenzel L., Malinowska A., Slabicki M., Zenz T., Zerrouqi A., Golab J., Winiarska M. (2017). HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. Blood 130(14):1628-1638. doi: 10.1182/blood-2016-08-736066. http://www.bloodjournal.org/content/130/14/1628

 2016

 Słabicki M., Lee K.S., Jethwa A., Sellner L., Sacco F., Walther T., Hüllein J., Dietrich S., Wu B., Lipka D.B., Oakes C.C., Mamidi S., Pyrzyńska B., Winiarska M., Oleś M., Seifert M., Plass C., Kirschfink M., Boettcher M., Gołąb J., Huber W., Fröhling S., Zenz T. (2016). Dissection of CD20 regulation in lymphoma using RNAi. Leukemia 30(12):2409-2412. doi:10.1038/leu.2016.230. https://www.nature.com/articles/leu2016230

2015

Dwojak M., Bobrowicz M., Bil J., Bojarczuk K., Pyrzynska B., Siernicka M., Malenda A., Lech-Maranda E., Tomczak W., Giannopoulos K., Golab J., Winiarska M. (2015). Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins. Blood Cancer J. 5:e300. doi: 10.1038/bcj.2015.27. https://www.nature.com/articles/bcj201527

Toruń A., Szymańska E., Castanon I., Wolińska-Nizioł L., Bartosik A., Jastrzębski K., Miętkowska M., González-Gaitán M., Miaczynska M. (2015). Endocytic Adaptor Protein Tollip Inhibits Canonical Wnt Signaling. PLoS One 10(6):e0130818. doi: 10.1371/journal.pone.0130818. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0130818

 2014

 Zerrouqi A., Pyrzynska B., Brat D.J., Van Meir E.G. (2014). P14ARF suppresses tumor-induced thrombosis by regulating the tissue factor pathway Cancer Res. 74, 1371-8. doi: 10.1158/0008-5472.CAN-13-1951. http://cancerres.aacrjournals.org/content/74/5/1371.long

Bojarczuk K., Siernicka M., Dwojak M., Bobrowicz M., Pyrzynska B., Gaj P., Karp M., Giannopoulos K., Efremov D.G., Golab J., Winiarska M. (2014).  B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies. Leukemia 28, 1163-7. doi: 10.1038/leu.2014.12. https://www.nature.com/articles/leu201412

Winiarska M., Bojarczuk K., Pyrzynska B., Bil J., Siernicka M., Dwojak M., Bobrowicz M.,  Miazek N., Zapala P., Zagozdzon A., Krol M., Syta A., Podszywalow-Bartnicka P., Pilch Z., Dabrowska-Iwanicka A., Juszczynski P., Efremov D.G., Slabicki M.,  Zenz T., Le Roy A., Olive D., Rygiel T.P.,  Leusen J., Golab J. (2014). Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies. mAbs 6, 1300-13. doi: 10.4161/mabs.32106. https://www.tandfonline.com/doi/full/10.4161/mabs.32106